Physician profile
Jay Harvey
NPI 1235247404
$670.20
in general payments reported to CMS, 2019-2025
14 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.68 · 2020: $41.79 · 2021: $125 · 2022: $109 · 2023: $15.26 · 2024: $181 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $238.74 | 2021-2025 | |
| Novo Nordisk INC | $85.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $55.93 | 2022-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $47.82 | 2020-2025 | Breztri |
| Exact Sciences Corporation | $35.60 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $33.19 | 2024-2025 | |
| Allergan, INC. | $27.98 | 2020 | |
| Boston Scientific Corporation | $25.20 | 2024 | Wavewriter Alpha Prime 16 |
| Antares Pharma, INC. | $23.73 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.33 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.45 | 2022 | |
| Si-Bone, INC. | $17.27 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.63 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.